These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16371875)

  • 1. Posttransplant lymphoproliferative disease.
    Soltys K; Green M
    Pediatr Infect Dis J; 2005 Dec; 24(12):1107-8. PubMed ID: 16371875
    [No Abstract]   [Full Text] [Related]  

  • 2. The antiviral prophylaxis of post-transplant lymphoproliferative disorder.
    Davis CL
    Springer Semin Immunopathol; 1998; 20(3-4):437-53. PubMed ID: 9870256
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone.
    Trappe R; Riess H; Anagnostopoulos I; Neuhaus R; Gärtner BC; Pohl H; Müller HP; Jonas S; Papp-Vary M; Oertel S
    Ann Hematol; 2009 Feb; 88(2):167-72. PubMed ID: 18636261
    [No Abstract]   [Full Text] [Related]  

  • 4. Posttransplant lymphoproliferative disorder.
    Everly MJ; Bloom RD; Tsai DE; Trofe J
    Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus-related lymphoproliferative disorders.
    Wagner-Johnston ND; Ambinder RF
    Curr Hematol Malig Rep; 2007 Oct; 2(4):249-54. PubMed ID: 20425377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
    Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
    Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment advances in posttransplant lymphoproliferative disease.
    DiNardo CD; Tsai DE
    Curr Opin Hematol; 2010 Jul; 17(4):368-74. PubMed ID: 20473161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
    Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R
    Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder of plasma cell type following allogeneic haemopoietic stem cell transplant treated with rituximab.
    Getta B; Kwan J
    Intern Med J; 2014 Aug; 44(8):821. PubMed ID: 25081050
    [No Abstract]   [Full Text] [Related]  

  • 10. Posttransplant lymphoproliferative disease, monoclonal, Epstein-Barr virus related.
    Petrovic LM
    Liver Transpl; 2001 May; 7(5):451-2. PubMed ID: 11349267
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of T- and NK-cell-targeted therapies: is there a role for rituximab prophylaxis?
    Ambinder RF
    Clin Cancer Res; 2009 Apr; 15(7):2205-6. PubMed ID: 19293254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients.
    Allen U; Preiksaitis J;
    Am J Transplant; 2009 Dec; 9 Suppl 4():S87-96. PubMed ID: 20070701
    [No Abstract]   [Full Text] [Related]  

  • 13. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation.
    Allen UD; Preiksaitis JK;
    Am J Transplant; 2013 Mar; 13 Suppl 4():107-20. PubMed ID: 23465004
    [No Abstract]   [Full Text] [Related]  

  • 14. Epstein-Barr virus and posttransplant lymphoproliferative disease.
    Holmes R
    J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):442-4. PubMed ID: 11698760
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab.
    Maldonado NI; Cabanillas F; Jaffe ES; Raffeld M; Lozada L
    J Clin Oncol; 2011 Aug; 29(22):e658-60. PubMed ID: 21646613
    [No Abstract]   [Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disorders.
    Singavi AK; Harrington AM; Fenske TS
    Cancer Treat Res; 2015; 165():305-27. PubMed ID: 25655616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update.
    Dierickx D; Tousseyn T; De Wolf-Peeters C; Pirenne J; Verhoef G
    Leuk Lymphoma; 2011 Jun; 52(6):950-61. PubMed ID: 21338285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
    Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O
    J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J; Kotloff R; Tsai DE
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.